ATE473973T1 - Substituierte benzimidazole und deren verwendung zur induktion von apoptose - Google Patents
Substituierte benzimidazole und deren verwendung zur induktion von apoptoseInfo
- Publication number
- ATE473973T1 ATE473973T1 AT05707991T AT05707991T ATE473973T1 AT E473973 T1 ATE473973 T1 AT E473973T1 AT 05707991 T AT05707991 T AT 05707991T AT 05707991 T AT05707991 T AT 05707991T AT E473973 T1 ATE473973 T1 AT E473973T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- formula
- inducing apoptosis
- group
- neoplastic
- Prior art date
Links
- 230000006907 apoptotic process Effects 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- -1 ethylenecarbonyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04405082 | 2004-02-11 | ||
| PCT/EP2005/050586 WO2005077939A1 (en) | 2004-02-11 | 2005-02-10 | Substituted benzimidazoles and their use for inducing apoptosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE473973T1 true ATE473973T1 (de) | 2010-07-15 |
Family
ID=34684811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05707991T ATE473973T1 (de) | 2004-02-11 | 2005-02-10 | Substituierte benzimidazole und deren verwendung zur induktion von apoptose |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20070167505A1 (de) |
| EP (1) | EP1723138B1 (de) |
| JP (1) | JP4890270B2 (de) |
| CN (1) | CN1918148B (de) |
| AT (1) | ATE473973T1 (de) |
| CA (1) | CA2553704C (de) |
| DE (1) | DE602005022284D1 (de) |
| DK (1) | DK1723138T3 (de) |
| ES (1) | ES2346323T3 (de) |
| WO (1) | WO2005077939A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| MY149870A (en) * | 2006-06-21 | 2013-10-31 | Sanofi Aventis | Dna fragmentation assay |
| CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| JP5628828B2 (ja) | 2008-12-19 | 2014-11-19 | サートリス ファーマシューティカルズ， インコーポレイテッド | チアゾロピリジンサーチュイン調節化合物 |
| MX336240B (es) * | 2009-07-27 | 2016-01-13 | Basilea Pharmaceutica Ag | Furazanobencimidazoles como profarmacos para tratar las enfermedades neoplasicas o autoinmunologicas. |
| CN102869353A (zh) * | 2010-05-06 | 2013-01-09 | 诺瓦提斯公司 | 自身免疫疾病的治疗 |
| US9303024B2 (en) | 2011-10-11 | 2016-04-05 | Dana-Farber Cancer Institute, Inc. | Pyrazol-3-ones that activate pro-apoptotic BAX |
| US9512120B2 (en) | 2013-03-15 | 2016-12-06 | Syngenta Participations Ag | Microbicidally active imidazopyridine derivatives |
| WO2016202758A1 (en) * | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds |
| WO2019097073A1 (en) * | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| GB202101734D0 (en) * | 2021-02-08 | 2021-03-24 | Cerevance Inc | Novel Compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1670916A1 (de) * | 1967-08-29 | 1971-04-08 | Bayer Ag | Verfahren zur Herstellung neuartiger Carbamidsaeureester |
| US6369092B1 (en) * | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
| US6211177B1 (en) * | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
| US20050038022A1 (en) * | 2001-03-26 | 2005-02-17 | Unisearch Limited | Method for treatment of cancer and compositions for use therein |
| WO2002098425A1 (en) * | 2001-06-04 | 2002-12-12 | Cytovia, Inc. | Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| TWI335913B (en) * | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| EP1636215B1 (de) * | 2003-05-23 | 2008-01-23 | Basilea Pharmaceutica AG | Furazanobenzimidazole |
-
2005
- 2005-02-10 CA CA2553704A patent/CA2553704C/en not_active Expired - Fee Related
- 2005-02-10 DE DE602005022284T patent/DE602005022284D1/de not_active Expired - Lifetime
- 2005-02-10 EP EP05707991A patent/EP1723138B1/de not_active Expired - Lifetime
- 2005-02-10 CN CN2005800045340A patent/CN1918148B/zh not_active Expired - Fee Related
- 2005-02-10 US US10/587,675 patent/US20070167505A1/en not_active Abandoned
- 2005-02-10 DK DK05707991.5T patent/DK1723138T3/da active
- 2005-02-10 AT AT05707991T patent/ATE473973T1/de active
- 2005-02-10 JP JP2006552624A patent/JP4890270B2/ja not_active Expired - Fee Related
- 2005-02-10 ES ES05707991T patent/ES2346323T3/es not_active Expired - Lifetime
- 2005-02-10 WO PCT/EP2005/050586 patent/WO2005077939A1/en not_active Ceased
-
2006
- 2006-08-09 US US11/501,648 patent/US7423157B2/en not_active Expired - Fee Related
-
2008
- 2008-07-16 US US12/173,869 patent/US7951957B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2346323T3 (es) | 2010-10-14 |
| CN1918148B (zh) | 2012-09-05 |
| US7423157B2 (en) | 2008-09-09 |
| CA2553704A1 (en) | 2005-08-25 |
| US20080287681A1 (en) | 2008-11-20 |
| WO2005077939A1 (en) | 2005-08-25 |
| US20070066670A1 (en) | 2007-03-22 |
| US7951957B2 (en) | 2011-05-31 |
| CN1918148A (zh) | 2007-02-21 |
| DK1723138T3 (da) | 2010-08-23 |
| EP1723138A1 (de) | 2006-11-22 |
| JP4890270B2 (ja) | 2012-03-07 |
| CA2553704C (en) | 2011-04-19 |
| JP2007522188A (ja) | 2007-08-09 |
| US20070167505A1 (en) | 2007-07-19 |
| DE602005022284D1 (de) | 2010-08-26 |
| EP1723138B1 (de) | 2010-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110952T1 (el) | Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3 | |
| CY1107422T1 (el) | Φουραζανοβενζιμιδαζoλες | |
| DE602004011199D1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
| SE0202133D0 (sv) | Novel compounds | |
| ATE517882T1 (de) | Chinolinderivate | |
| WO2006039718A3 (en) | Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors | |
| EA200601266A1 (ru) | Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата | |
| EA200801998A1 (ru) | ПИРИДИН[3,4-b]ПИРАЗИНОНЫ | |
| TNSN07361A1 (en) | 3,4-substituted pyrrolidine derivatives for the treatment of hypertension | |
| NZ595759A (en) | Substituted phenylureas and phenylamides as vanilloid receptor ligands | |
| TW200621777A (en) | New dihydropteridione derivatives, process for their manufacture and their use as medicament | |
| TW200621262A (en) | New dihydropteridione derivatives, process for their manufacture and their use as medicament | |
| CY1113573T1 (el) | Selurampanel | |
| SE0401762D0 (sv) | Novel compounds | |
| ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| ATE473973T1 (de) | Substituierte benzimidazole und deren verwendung zur induktion von apoptose | |
| DE602008001725D1 (de) | 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus | |
| TW200612936A (en) | Indole derivatives | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| EA201170722A1 (ru) | Лактамы в качестве ингибиторов бета-секретазы | |
| TW200616979A (en) | Non-nucleoside reverse transcriptase inhibitors | |
| SE0402925D0 (sv) | Novel Compounds | |
| MXPA05010020A (es) | Derivados de oxamida. | |
| BR0314352A (pt) | Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6 | |
| ATE482933T1 (de) | Sulfopyrrolderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1723138 Country of ref document: EP |